Drug Safety
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Mrinalini Dey DrMiniDey
3 years 10 months ago
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Eric Dein ericdeinmd
3 years 10 months ago
#ACR21 Ab#1681: ATI-450- MK2 Inhibitor
⭐️Downstream MK2 mediated inflamm drive of p38.
⭐️Hope this would avoid tachyphylaxis in p38 inhibitor meds
▶️Phase2a study in 19 pts: Well-tolerated (SEs: UTI, ventricular extrasystole), good 12 week data
@Rheumnow https://t.co/6lo7zPJUpx
Mrinalini Dey DrMiniDey
3 years 10 months ago
SELECT-EARLY results for #upadacitinib in #RA
👉🏼UPA better than MTX for clinical response and remission
👉🏼⬆️rates of HZ, neutropenia, CPK elevations
👉🏼No new safety risks identified
Abs#1692 #ACR21 @RheumNow
https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Pedro Castillo _Castillo_Pedro
3 years 11 months ago
Upadacitinib 56-wk efficacy/safety (mod to severe PsA)
🔹Comparable or ⬆️efficacy vs adalimumab
🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks
🔹No new safety findings @ 56wks
🔹🚫inc risk VTE, MACE, cancer vs ada
https://t.co/NlKvBrwDxB
#ACR21 Abst#1345 @RheumNow
Mithu Maheswaranathan, MD MithuRheum
3 years 11 months ago
🆕 Updated 2021 ACR Guidance for Adjusting Immunomodulatory Therapy with the COVID-19 Vaccine in Patients with Rheumatic & MSK Diseases
Discussed at #ACR21 COVID-19 Hub!
V4 Link: https://t.co/1SOR9yTQyF https://t.co/PKFKXpLofN
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
Poster Hall